Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review.

Infect Drug Resist · 2019 · PMC6556539 · PMID 31239725

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Survival outcome was assessed as a secondary endpoint; there was a trend towards lower all-cause mortality among allogeneic HSCT recipients who received letermovir prophylaxis, but this did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.